Novartis (Novn) Profit Q1 20225: Sales Kisqali Soar

Swiss pharmaceutical firm Novartis On Thursday, he expected that his breast cancer treatment would be the next blockbuster in his portfolio, as he seems to have moved from dependence on heart failure.

Sales of Kisqali, which treats metastatic breast cancer, increased by 64% three months to June, the company reports in its second quarter sales report. These include 100% growth in the US

This implies an increase in Kisqali sales by 56% in the first quarter to March.

Speaking on the call call, the CEO of you Naromsaman stated that Kiskali was a drug with the largest sphere for the results.

According to the World Health Organization, global diagnoses and breast cancer deaths will increase, the World Health Organization reports CancerWith 1 of 20 women worldwide, breast cancer is expected to be diagnosed with life.

This can lead to 3.2 million new cases and 1.1 million deaths per year by 2050, when modern trends are ongoing, the study has revealed significantly above 2.3 million new cases and 670,000 deaths.

Naromsaman also cited the “strong pipeline” of Novartis of other drugs, including his prostate cancer treatment and Scemblix for chronic myeloid leukemia, which he said was also “on the way to the blockbuster.”

“We still move high performance on our permanent launches for Kisqali, Pluvicto and Scemblix, demonstrating the replacement power in our portfolio,” he added in a statement that accompanies the results.

The comments come when Novartis seeks to shake their dependence on its highest selling drug, which is facing the expiration of the US patent next year. In 2024, Ertesto brought $ 7.8 billion, accounting for about 15% of the total global sales of the company.

On Thursday, it is said that the genetic manufacturers of drugs will start to produce copy versions of the drug by mid -2015, although this term “is subject to a permanent IC (intellectual property) and normative lawsuits.”

On Wednesday the US federal judge rejected Novartis’s request on a preliminary ban To stop the MSN Pharmaceuticals from the sale of the overall version of the drug before expiry of the patent.

In the second quarter, Estevest rose by 22%, according to the previous three -month period.

“Short-term is an important product for us,” said Harry Kirsh Kirsch, Chief Financial Director on Thursday.

“We have an IP that we defend. If we succeed in further protection of our attractiveness, every month we will have some pleasant significant crossings,” he added.

Overall, net sales in the second quarter novartis increased by 11% on a permanent currency to $ 14.05 billion, only ashamed of $ 14.18 billion, estimated by analysts in LSEG poll.

Meanwhile, the main operating income has increased by 21% to $ 5.93 billion, which is just above $ 5.69 billion.

Novartis said he expects the full -year operating income on “low teens”, which is compared to “low double -digit”, while it retained sales growth forecast in high definite figures.

The company also announced the ransom of shares to $ 10 billion, citing “confidence” in its growth of medium and long -term growth.